
    
      This will be a 3-arm randomized, multicenter, double-masked, placebo-controlled study
      conducted in 2 stages.

      Stage 1 is a safety and efficacy phase of 3 years in duration, during which subjects will be
      allocated to 1 of 3 study medications.

      Stage 2 is a randomized cross-over phase of 1 year in duration, during which subjects will be
      re-randomized to receive 1 of the 3 study medications, with subjects initially randomized to
      Vehicle only eligible for randomization to low or high-dose NVK-002.

      Treatment arms are:

        -  NVK-002 low dose concentration

        -  NVK-002 high dose concentration

        -  Vehicle (placebo)
    
  